Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
2026-07-22 09:30
•James Brumley •The Motley Fool
•• ••••••• Axe Capital view
Why Cathie Wood’s CRISPR Bet is Worth Watching from SA
Ark’s sizable investment in CRISPR Therapeutics highlights a gene therapy play that could grow faster than many expect, even from South Africa.
Cathie Wood is backing CRISPR Therapeutics with over $360 million, signaling real conviction in gene editing’s future. Beyond their approved sickle cell drug Casgevy, CRISPR's push into off-the-shelf CAR T-cell therapies offers a cheaper, scalable alternative to traditional patient-specific treatments. That’s crucial because CAR T therapies could become a $60 billion market by 2034, growing at about 30% per year. While this space still faces clinical and regulatory hurdles, the potential payoff is huge. South African investors might see parallels where big healthcare and biotech bets usually feel out of reach, but the USD/ZAR rate (right now roughly 19 to 20) makes accessing global innovators like CRISPR more affordable than before. However, it’s still early days, and trial setbacks could hit the stock hard. If you prefer local counters, opportunities in higher-tech segments are limited, so a cautious allocation via international ETFs like ARKK or ARKG could be sensible. this is just my opinion and not financial advice
I’d allocate a small, speculative portion of growth capital to global biotech ETFs holding CRISPR, especially ARKK, while monitoring rand moves closely. Avoid direct SA healthcare names for now; the local innovation isn’t in this niche yet.
- CRSP
- ARKK
- USD/ZAR
- clinical trial failures
- regulatory delays
- rand volatility
6/10
Cathie Wood's Ark Investment Management holds $362 million in CRISPR Therapeutics across two ETFs. While known for gene-editing work like the FDA-approved Casgevy, the company is quietly developing CAR T-cell therapies that could address a market projected to exceed $60 billion annually by 2034. CRISPR's off-the-shelf CAR T approach using donor cells could reduce costs compared to patient-specific treatments, positioning it competitively despite being in early trial stages.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: James Brumley
Categories: Healthcare, Equities
Tickers: CRSP, ARKK, ARKG, NVS, BMY, CELGR, GILD
Sentiment: Positive - The article highlights CRISPR's underrated CAR T-cell therapy development program alongside its approved Casgevy drug. The CAR T approach offers cost advantages through off-the-shelf donor cell treatments, and the market is projected to grow 30% annually through 2034. Cathie Wood's substantial $362 million investment signals confidence in the company's multiple growth catalysts. The ETF holds nearly $270 million in CRISPR Therapeutics, reflecting Cathie Wood's conviction in the company's growth potential. The article frames this as a well-considered investment backed by underappreciated catalysts.
Keywords: CRISPR Therapeutics, gene editing, CAR T-cell therapy, Casgevy, Cathie Wood, Ark Investment Management, biotech, FDA approval
Insights:
- CRSP: Positive: The article highlights CRISPR's underrated CAR T-cell therapy development program alongside its approved Casgevy drug. The CAR T approach offers cost advantages through off-the-shelf donor cell treatments, and the market is projected to grow 30% annually through 2034. Cathie Wood's substantial $362 million investment signals confidence in the company's multiple growth catalysts.
- ARKK: Positive: The ETF holds nearly $270 million in CRISPR Therapeutics, reflecting Cathie Wood's conviction in the company's growth potential. The article frames this as a well-considered investment backed by underappreciated catalysts.
- ARKG: Positive: The ETF holds $92 million in CRISPR Therapeutics, further demonstrating Ark's confidence in gene-editing and genomic innovation as a long-term investment theme.